The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology

蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖

• 批准号: 10434380
• 负责人: Nina Bhardwaj
• 金额: $ 5.4万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10434380
• 关键词: Address; Basic Science; Cancer Intervention; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Clinical Sciences; Clinical Trials; Data Science; Development; Doctor of Philosophy; Entrepreneurship; Environment; Evaluation; Faculty; Funding; Future; Goals; Immunotherapeutic agent; Individual; Institutes; Interdisciplinary Communication; Intervention Trial; Justice; K-Series Research Career Programs; Knowledge; Leadership; Learning; Malignant Neoplasms; Master of Science; Medicine; Mentors; Methodology; Oncologist; Oncology; Outcome; Pharmaceutical Preparations; Population; Professional Competence; Program Development; Research; Research Activity; Research Personnel; SECTM1 gene; Schools; Science; Structure; Talents; Therapeutic; Training; Training and Education; Translational Research; United States National Institutes of Health; anti-racism; anticancer research; cancer immunotherapeutics; cancer therapy; career; career development; drug discovery; education research; equity diversity and inclusion; faculty community; innovation; medical specialties; multidisciplinary; multiple omics; next generation; novel; patient oriented; patient oriented research; pedagogy; precision medicine clinical trials; programs; recruit; resilience; response; social; success; tool

SUMMARY/ABSTRACT: The purpose of our proposed Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology (K12) is to catalyze the clinical and translational research career development of inspired clinical oncologists from diverse oncology specialties and backgrounds, to become future innovative, scientifically grounded and impactful leaders in clinical cancer research and interventional trials. The intent of our K12 is to advance the careers of the next generation of independently funded interdisciplinary Scholars, armed with the methodologic and analytical acumen, scientific knowledge, teaming capacity and career skills required to successfully address specific unmet needs in cancer treatment, which significantly impact our catchment relevant population. Our strongly mentored career development 3 year program for early stage (junior faculty) investigators, will capitalize upon the Tisch Cancer Institute's expertise in cancer immunotherapeutics, novel correlates of immunotherapeutic response, integrative multi- omic platforms to inform drug repositioning approaches; outstanding cadre of Clinical and Translational Mentors; diverse pool of compelling Scholars, and an academically rigorous training environment that prepares the most compelling MD, or MD/PhD junior faculty in clinical oncology for careers in patient oriented research. Our curricular and mentored research activities will additionally leverage institutional strengths in Data Science, Drug Discovery and Precision Medicine: clinical trial methodology; innovative clinical and translational research education and pedagogy, including opportunities to earn a Master's of Science or PhD in Clinical Research, offered through the Clinical Research Education Program in the Graduate School of Biomedical Sciences and CTSA Center for Patient Oriented Research Training, Education and Development (CePORTED); and align with the NIH UNITE and our institutional anti-racist agenda and commitment to recruit and retain talented underrepresented individuals in medicine and science (URiMS). To accomplish our goals, we will pursue the following specific aims: Aim 1: Champion a structured, educational, scholar specific development program to prepare clinical oncologists to conduct cutting edge, hypothesis -driven and practice changing research in cancer therapeutics; Aim 2: Provide Co-Mentored (Basic and Clinical science faculty) and community informed clinical trial research opportunities in therapeutic innovation; Aim 3: Build a patient oriented cancer research learning culture to advance therapeutic innovation by delivering cutting edge multidisciplinary career development opportunities to advance team science, leadership, cross-disciplinary communication, resilience, and entrepreneurship; Aim 4: Advance justice, equity, diversity and inclusion as core tenets of socially responsible clinical investigators; and Aim 5: Implement a comprehensive, rigorous and quality improvement approach, to program, trainee and mentor evaluation, utilizing novel tools, to track milestones as well as outcome metrics of success.

概要/摘要：我们提议的Tisch癌症研究所（TCI）Paul Calabresi K12的目的 临床肿瘤学职业发展奖（K12）旨在促进临床和转化研究 来自不同肿瘤学专业和背景的临床肿瘤学家的职业发展， 成为未来临床癌症研究的创新，科学和有影响力的领导者， 干预性试验我们的K12的目的是推动下一代独立的职业生涯 受资助的跨学科学者，拥有方法论和分析敏锐性，科学知识， 成功解决癌症治疗中未满足的具体需求所需的团队合作能力和职业技能， 这对我们的流域相关人口产生了重大影响。我们的职业发展辅导3 一个为期一年的早期阶段（初级教师）研究计划，将利用Tisch癌症研究所的 癌症免疫治疗的专业知识，免疫应答的新相关性， 为药物重新定位方法提供信息的组学平台;临床和转化的优秀骨干 导师;令人信服的学者的多样化池，以及学术上严格的培训环境， 最引人注目的医学博士，或医学博士/博士初级教师在临床肿瘤学的职业生涯中以病人为导向的研究。 我们的课程和指导研究活动将进一步利用数据科学的机构优势， 药物发现和精准医学：临床试验方法学;创新临床和转化研究 教育和教学法，包括获得科学硕士或临床研究博士学位的机会， 通过生物医学科学研究生院的临床研究教育计划提供， CTSA面向患者的研究培训、教育和发展中心（CePORTED）;并与 与美国国立卫生研究院团结和我们的机构反种族主义议程和承诺，以招募和留住人才， 医学和科学领域代表性不足的个人（URiMS）。为了实现我们的目标，我们将继续 目标1：支持一个结构化的、教育性的、学者特定的发展计划， 准备临床肿瘤学家进行前沿，假设驱动和实践改变研究， 癌症治疗;目标2：提供共同指导（基础和临床科学教师）和社区知情 治疗创新中的临床试验研究机会;目标3：建立以患者为导向的癌症研究 学习文化，通过提供尖端的多学科职业来推进治疗创新 发展机会，以推进团队科学、领导力、跨学科沟通、韧性， 目标4：促进正义、公平、多样性和包容，作为社会发展的核心原则 目标5：实施全面、严格的质量改进 方法，计划，学员和导师评估，利用新的工具，跟踪里程碑以及 成功的结果指标。